Briefing
Circulating tumor DNA (ctDNA) in patients with MIBC who received perioperative durvalumab in NIAGARA.
Baseline ctDNA+ 57% (260/460), pre-RC 22% (94/422).
- Design: Exploratory plasma ctDNA in NIAGARA
- n: BEP 462 of 1063 (237 D, 225 C)
- Assay: Signatera, tumor-informed (Natera)